Touyun Biotech Group Limited Issues Positive Profit Alert: Significant Turnaround Expected for FY2025

Key Highlights

• Profit Expectation: Touyun Biotech Group Limited anticipates recording a profit of no less than HK\$55 million for the year ended 31 December 2025, marking a substantial turnaround from the previous year’s loss of approximately HK\$79 million.
• Major Contributing Factor: The reversal from loss to profit is primarily due to a fair value gain on financial assets at fair value through profit or loss, specifically from both unlisted and listed equity investments. This gain is estimated at HK\$129 million, compared to a fair value loss of approximately HK\$38 million recorded in 2024.
• Management Assessment: The figures are based on preliminary assessment of unaudited consolidated management accounts, and may be subject to further adjustments pending additional information and audit committee review.
• Upcoming Financial Announcement: The audited results for FY2025 will be officially released on or before the end of March 2026.

Critical Information for Shareholders

• Potential Share Price Impact: The positive profit alert, especially following a significant loss last year, is likely to be price sensitive and could influence investor sentiment and the Company’s share value.
• Fair Value Gain Details: The remarkable swing—from a fair value loss in 2024 to a substantial gain in 2025—signals improved performance in the Company’s investment portfolio, which is a key driver for the turnaround.
• Caution Advised: Shareholders and potential investors are urged to exercise caution when dealing in the Company’s shares, as the current figures are unaudited and may change after the audit committee’s review.

Board & Corporate Governance

The announcement was made by Mr. Wang Liang, Chairman of Touyun Biotech Group Limited. The Board consists of executive directors (Mr. Wang Liang, Mr. Du Dong, Mr. Zhang Lele), non-executive directors (Mr. Chen Hui, Ms. Tian Yuze), and independent non-executive directors (Mr. Cheung Wing Ping, Mr. Ha Kee Choy Eugene, Mr. To Shing Chuen). This diverse board structure ensures comprehensive oversight and governance.

Investor Outlook

This positive profit alert represents a significant recovery in Touyun Biotech’s financial performance, largely driven by improved investment returns. Investors should closely monitor the Company’s forthcoming results announcement, which will provide audited details and confirm the preliminary figures. Any changes to these numbers could further impact the Company’s share price, making this disclosure highly relevant for both current and prospective shareholders.

Disclaimer

The information above is based on preliminary unaudited management accounts and may be subject to further revision. Investors should await the official audited results announcement for definitive figures. This article does not constitute investment advice. Please exercise caution and consult your financial advisor before making investment decisions.

View TOUYUN BIOTECH Historical chart here